Foot massager toronto

i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource. This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and Associate Division Director for Ambulatory Operations The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma. STATEMENT OF NEED Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL. Target Audience Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL). Learning Objectives 1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL 2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults 3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection

Light House Retreats: Plant Medicine Retreat Europe

Lighthouse Retreat

Evaluation of antidepressant activity of clitoris ternatea in animals

Shweta

planning for change nursing Management ppt

Thangamjayarani

KDIGO 2024 guidelines for diabetologists

د.محمود نجيب

Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe

Savita Shen $i11

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Oleg Kshivets

RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.

Physiology of Chemical Sensation of smell.pdf

MedicoseAcademics

Title: Sense of Smell Presenter: Dr. Faiza, Assistant Professor of Physiology Qualifications: MBBS (Best Graduate, AIMC Lahore) FCPS Physiology ICMT, CHPE, DHPE (STMU) MPH (GC University, Faisalabad) MBA (Virtual University of Pakistan) Learning Objectives: Describe the primary categories of smells and the concept of odor blindness. Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction. Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain. Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential. Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes. Key Topics: Olfactory Genes: 3% of the human genome accounts for olfactory genes. 400 genes for odorant receptors. Olfactory Membrane: Located in the superior part of the nasal cavity. Medially: Folds downward along the superior septum. Laterally: Folds over the superior turbinate and upper surface of the middle turbinate. Total surface area: 5-10 square centimeters. Olfactory Mucosa: Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell. Sustentacular Cells: Produce mucus and maintain ionic and molecular environment. Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months. Bowman’s Gland: Secretes mucus. Stimulation of Olfactory Cells: Odorant dissolves in mucus and attaches to receptors on olfactory cilia. Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve. Quality of a Good Odorant: Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble. Facilitated by odorant-binding proteins in mucus. Membrane Potential and Action Potential: Resting membrane potential: -55mV. Action potential frequency in the olfactory nerve increases with odorant strength. Adaptation Towards the Sense of Smell: Rapid adaptation within the first second, with further slow adaptation. Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system. Primary Sensations of Smell: Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid. Odor Detection Threshold: Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm). Some toxic substances are odorless at lethal concentrations. Characteristics of Smell: Odor blindness for single substances due to lack of appropriate receptor protein. Behavioral and emotional influences of smell. Transmission of Olfactory Signals: From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition. Primitive, less old, and new olfactory systems with different path

Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx

Dr. Rabia Inam Gandapore

Non-respiratory Functions of the Lungs.pdf

MedicoseAcademics

These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract. Learning objectives: 1. Enlist the non-respiratory functions of the respiratory tract 2. Briefly explain how these functions are carried out 3. Discuss the significance of dead space 4. Differentiate between minute ventilation and alveolar ventilation 5. Describe the cough and sneeze reflexes Study Resources: 1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition 2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition 3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition 4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874

Knee anatomy and clinical tests 2024.pdf

vimalpl1234

ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS

Dr. Vinay Pareek

New Drug Discovery and Development .....

NEHA GUPTA

The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.

BRACHYTHERAPY OVERVIEW AND APPLICATORS

Krishan Murari

TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...

kevinkariuki227

Recently uploaded (20)

Ocular injury ppt Upendra pal optometrist upums saifai etawah

MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf

Cervical & Brachial Plexus By Dr. RIG.pptx

Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun

Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

Light House Retreats: Plant Medicine Retreat Europe

Evaluation of antidepressant activity of clitoris ternatea in animals

planning for change nursing Management ppt

KDIGO 2024 guidelines for diabetologists

Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Physiology of Chemical Sensation of smell.pdf

Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx

Non-respiratory Functions of the Lungs.pdf

Knee anatomy and clinical tests 2024.pdf

ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS

New Drug Discovery and Development .....

BRACHYTHERAPY OVERVIEW AND APPLICATORS

TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...

Foot massager toronto

1. Welcome To Massage Chair Toronto

2. About us AcuRelax is a Canadian corporation, promoted by medical professionals and professional Engineers. All AcuRelax products are designed and thoroughly tested by our team of doctors and therapists. AcuRelax products are manufactured in ISO 9001 certified facilities under strict quality control. Our products are ETL/UL/CSA approved. Product quality is ensured by the team of Professional engineers at AcuRelax's parent company: MECS Engineering Inc. MECS is a member of Professional Engineers Ontario (PEO) and has been incorporated in Canada since 2006. Our Mission is to provide our customers a relaxing, rejuvenating experience through the use of our high quality health and wellness products at an affordable price.

3. Massage Chair Toronto

4. Massage Chair Toronto

5. Contact us Website :- http://www.acurelax.com

6. Thanks For Watching

Foot massager toronto

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (20)

Similar to Foot massager toronto

Similar to Foot massager toronto (7)

Recently uploaded

Recently uploaded (20)

Foot massager toronto